Prognostic Factors Influencing the Efficacy of Regorafenib in the Treatment of Metastatic Colorectal Cancer
Aim: Metastatic colorectal cancer (mCRC) remains a significant clinical challenge for patients who have exhausted standard treatment options. Regorafenib, an oral multikinase inhibitor, is approved for use in refractory with mCRC patients; however, its real-world efficacy continues to be an area of...
Saved in:
Main Authors: | Nadiye SEVER, İbrahim Vedat BAYOĞLU |
---|---|
Format: | Article |
Language: | English |
Published: |
Galenos Yayincilik
2025-06-01
|
Series: | Namık Kemal Tıp Dergisi |
Subjects: | |
Online Access: | https://namikkemalmedj.com/articles/prognostic-factors-influencing-the-efficacy-of-regorafenib-in-the-treatment-of-metastatic-colorectal-cancer/doi/nkmj.galenos.2025.34654 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY
by: N. A. Avxentyev, et al.
Published: (2016-09-01) -
Prolonged Survival Outcome in a Patient with Refractory Metastatic Colorectal Cancer Treated with Regorafenib Plus 5-Fluorouracil: A Case Report and Literature Review
by: Abdullah Esmail, et al.
Published: (2025-04-01) -
Autophagy inhibition improves sensitivity to the multi-kinase inhibitor regorafenib in preclinical mouse colon tumoroids
by: Giulia Agostini, et al.
Published: (2025-07-01) -
Effcacy and toxicity of regorafenib compared to reintrodaction of chemotherapy in metastatic colon cancer: retrospective multicenter study
by: E. S. Kuzmina, et al.
Published: (2023-09-01) -
Ongoing 5-year+ survival after multiple metastasectomies, followed by CAPOX plus bevacizumab, for metastatic colorectal cancer
by: Kozue Matsuishi, et al.
Published: (2020-06-01)